Log in to your Inderes Free account to see all free content on this page.
Cinclus Pharma
17.00 SEK
+1.92 %
Less than 1K followers
CINPHA
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+1.92 %
-3.08 %
+12.73 %
+8.42 %
-20.49 %
-14.23 %
-
-
-47.86 %
Cinclus Pharma is a Swedish pharmaceutical company in the clinical phase. The company is active in the development of molecules for the treatment of acid-related diseases. The company's leading drug candidate linaprazan glurate is being developed for the treatment of severe gastroesophageal reflux disease (GERD). Cinclus Pharma was founded in 2014 and has its headquarters in Stockholm.
Read moreMarket cap
805.67M SEK
Turnover
391.04K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
18.2.
2026
Annual report '25
13.5.
2026
Interim report Q1'26
21.5.
2026
General meeting '26
All
Webcasts
Press releases
ShowingAll content types
Cinclus Pharma invites to KOL event: insights on clinical practice for erosive Gastroesophageal Reflux Disease (GERD) patients
Redeye: Cinclus Pharma (Q3 review) - Pivotal studies underway
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
